Sudeep Pharma Submits Transcript of Q3 FY26 Earnings Call
Sudeep Pharma released its Q3 FY26 earnings call transcript. Q3 FY26 revenue grew 52% YoY to ₹179.2 crore, with PAT up 66% to ₹47.7 crore. Nine-month FY26 revenue increased 38% to ₹482.1 crore. The company is advancing its battery-grade iron phosphate project, with Phase 1 commissioning in early 2027. Significant capex of ₹550-600 crore is planned for battery materials.
The announcement details significant financial performance improvements and strategic developments, including capacity expansions and entry into new high-growth segments like battery materials. These factors are likely to have a substantial impact on the company's future growth and investor perception.
The company reported strong year-on-year financial growth in revenue, EBITDA, and PAT for both the quarter and nine months. Management discussed positive business momentum, strategic growth initiatives like battery materials, and upcoming capacity expansions, indicating a positive outlook.
Sudeep Pharma Limited has submitted the transcript of the analysts and investors conference call held on February 9, 2026, to discuss the unaudited financial results for the third quarter and nine months ended December 31, 2025.
The call featured insights from Managing Director Mr. Sujit Bhayani, Director Mr. Shanil Bhayani, and Chief Financial Officer Mr. Ketan Vyas.
Key highlights from the management included the company's evolution into a technology-driven global supplier of excipients and specialty ingredients, serving over 100 countries. The pharmaceutical, food, and nutrition segment contributes approximately 60% of revenue, while specialty ingredients account for about 40% and are a significant growth driver. The company reported strong momentum across regions, particularly in Asia-Pacific, Europe, and India.
Financially, for Q3 FY26, total income grew by 52% year-on-year to ₹179.2 crore, with EBITDA at ₹66.8 crore (up 60% YoY) and PAT at ₹47.7 crore (up 66% YoY). For the nine months ended December 2025, total income grew by 38% to ₹482.1 crore, with EBITDA at ₹181.5 crore and PAT at ₹125.7 crore.
Discussions also covered the progress of Sudeep Advanced Materials (SAM), focusing on battery-grade iron phosphate, with Phase 1 capacity of 25,000 metric tons per annum expected to be commissioned in early 2027. The company highlighted its differentiated ex-China supply chain position and ongoing customer engagements.
Capex plans were discussed, with a focus on the battery materials project estimated at ₹300 crore for Phase 1, and a total estimated capex of ₹550-600 crore for a 100,000-ton facility. The Nandesari Greenfield facility with a capacity of 51,200 metric tons is on track for commissioning in Q4 FY26 (March 2026).
The management addressed questions on revenue and margins excluding NSS, inventory and receivable days, the cost and moat advantage against Chinese suppliers for battery chemicals, liposomal chemistry applications, and capex plans for the next couple of years. They also discussed the seasonality of the business, ramp-up of new capacities, and the revenue potential and margin profile of the battery business.
What to do with a filing like this
Sudeep Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sudeep Pharma Limited. Read the original for the full detail.